Answers are grounded in this paper and cite their sources.
Introduction/Objective We present the case of a 35-year-old male with homozygous (HbSS) sickle cell disease (SCD), complicated by prior stroke, transfusion dependence, and extensive red cell alloimmunization (cold autoantibody (CAA), anti-C, -S, -Jsa, -Leb), who developed acute myeloid leukemia (AML) and a concurrent plasma cell neoplasm, unexpectedly identified after recently developed neutropenia in the prior few months. Methods/Case Report As part of his routine outpatient SCD management and follow-up on a recent hospital admission for a syncopal episode, a CBC and peripheral smear review were performed. Myeloid neoplasm was suspected following the identification of 8% blasts with bilobed morphology on peripheral smear. Bone marrow biopsy confirmed AML showing 28% blasts with bilobed morphology. Next-generation sequencing revealed pathogenic IDH1, STAG2, NRAS, and PTPN11 mutations. Karyotyping identified trisomy 5 and 7 (∼5% of cells), and a gain of 1q. Additionally, 10% kappa-restricted plasma cells were present on the biopsy, and two small M-spikes on serum protein electrophoresis. Results NA Conclusion This constellation of overlapping disorders with limited therapeutic options has a significantly guarded prognosis and led to the initiation of Azacitidine/Ivosidenib as a palliative strategy instead of induction chemotherapy. To our knowledge, this is the first reported case of coexisting SCD, AML, and plasma cell neoplasm.
No takes yet. Share an insight, caveat, or question.
Winkelmann et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: